Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001549595-25-000103
Filing Date
2025-08-01
Accepted
2025-08-01 17:09:02
Documents
1
Period of Report
2025-08-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1754082538.html 4  
1 FORM 4 wk-form4_1754082538.xml 4 3799
  Complete submission text file 0001549595-25-000103.txt   5353
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Issuer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address
van Houte Hans (Reporting) CIK: 0001817217 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39398 | Film No.: 251177046